Edgewise Therapeutics, Inc. (EWTX) stock
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$39.91−1.27 (-3.07%)
Close on Nov 20, 2026Market cap $4.33BP/E –Yield –
Edgewise Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Edgewise Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$158.83M. For fiscal 2025 it was -$144.07M. The highest annual figure on record is -$14.84M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$144.07M | – |
| FY2024 | Dec 31, 2024 | -$110.34M | – |
| FY2023 | Dec 31, 2023 | -$97.69M | – |
| FY2022 | Dec 31, 2022 | -$58.18M | – |
| FY2021 | Dec 31, 2021 | -$34.18M | – |
| FY2020 | Dec 31, 2020 | -$14.84M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.67M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$32.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.19M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.29M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.85M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.28M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.75M | – |
See a number that looks wrong?